Jaguar health names principal investigators for clinical trial to support full approval of canalevia-ca1 for treatment of chemotherapy-induced diarrhea (cid) in dogs

Canalevia®-ca1 is currently fda conditionally approved for treatment of cid in dogs and is the first and only treatment for cid in dogs to receive any type of approval from fda crofelemer, jaguar's novel, oral plant-based product sustainably harvested from the croton lechleri tree, is the active ingredient in canalevia-ca1 san francisco, ca / accesswire / july 26, 2023 / jaguar health, inc. (nasdaq:jagx), under its jaguar animal health tradename for the veterinary market, today announced that two leading veterinary oncologists, laura d. garrett, dvm, diplomate acvim (oncology) and angharad waite, vmd, dacvim (oncology), will serve as principal investigators for the company's planned clinical field study of canalevia®-ca1 (crofelemer delayed-release tablets), the company's u.s. food and drug administration (fda) conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (cid) in dogs, to support full approval of the product.
JAGX Ratings Summary
Quant
JAGX Quant Ranking
Sector
Industry
Quant Rating
Quant Score